Overview

Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

Status:
Recruiting
Trial end date:
2021-11-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects ≥1 month to <17 years of age undergoing MRI scans in the US and Japan.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Dexmedetomidine
Propofol